Skip to main content

NICE TAs

10/08/2020
TA290: Mirabegron for treating symptoms of overactive bladder
10/08/2020
TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
05/08/2020
TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
05/08/2020
TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration
05/08/2020
TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
05/08/2020
TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
05/08/2020
TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (replaced TA296)
05/08/2020
TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
05/08/2020
TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
05/08/2020
TA292: Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder
05/08/2020
TA509:Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
05/08/2020
TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
05/08/2020
TA297: Ocriplasmin for treating vitreomacular traction
29/07/2020
TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
29/07/2020
TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis
29/07/2020
TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
29/07/2020
TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
29/07/2020
TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
29/07/2020
TA401: Bosutinib for previously treated chronic myeloid leukaemia (replaced TA299)
29/07/2020
TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Follow AWTTC: